Escitalopram filed in Japan
H. Lundbeck A/S (Lundbeck) today announced that our partner MochidaPharmaceutical Co., Ltd. (Mochida) has filed a new drug application (NDA) forescitalopram for the treatment of depression with the Japanese Ministry ofHealth, Labour and Welfare (MHLW). If approved, Lundbeck expects thatescitalopram in Japan would be a meaningful contribution to Lundbeck's financialperformance already in the period 2012-2014. The commercialization of escitalopram will be supported by two highlyCNS-experienced Japanese companies which will co-market the product; Mochida andMitsubishi Tanabe Pharma